Thursday, November 12, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Meta Platforms: From Heavy AI CapEx to 2026 ROI?

View original at finance.yahoo.com
“Reality Labs (home to Meta's VR devices and metaverse projects) generated just over $2.1 billion in revenue but more than $17.7 billion in operating losses, remaining a clear drag on group profitability.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2025 capital expenditures will exceed $70 billion, approximately 70% higher than in 2024

    80% confidence

  • Time spent on Facebook rose 5% in Q3 2025

    80% confidence

  • Reels is running at a roughly $50 billion annualized revenue rate

    80% confidence

  • Threads usage jumped 10% in Q3 2025

    80% confidence

  • Instagram video consumption is up more than 30% year-over-year

    80% confidence

  • Meta has spent over $40 billion on R&D to date, with a significant portion allocated to AI/ML

    80% confidence

  • 2026 expenses will likely grow at a significantly faster rate than in 2025, largely due to infrastructure and personnel costs as new data center capacity comes online

    80% confidence

  • Lead-gen campaigns using Advantage+ show a 14% lower cost per lead than traditional campaigns

    80% confidence

  • Advantage+ is handling over $60 billion in annual ad spend

    80% confidence

  • Average price per ad rose 10% year-over-year in Q3 2025, credited to AI

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
Meta Platforms: From Heavy AI CapEx to 2026 ROI? — Source | Via News | Via News